The kappa opioid receptor may be a potential tumor suppressor by regulating angiogenesis in breast cancer

Our hypothesis proposes that activating κ-opioid receptors (KORs) may inhibit the progression of breast cancer and improve patient prognosis. Consequently, KORs may become a promising therapeutic target for breast cancer. Activating KORs induces not only analgesic efficacy comparable to μ-opioid receptors but also shows a promising antitumor effect and with fewer opioid-induced adverse effects. Based on present studies and our bioinformatics analysis of KORs, we propose that KORs can function as a tumor suppressor by inhibiting angiogenesis in human breast cancer; therefore, analgesics that mainly activate KORs would be more suitable for breast cancer patients.